← brief for 2026-10-03 · Slowing decline

Sequencing and combination of therapies in the cardiovascular-kidney-metabolic syndrome: GLP-1 RA, SGLT2 inhibitors, lipid-lowering drugs and mineralocorticoid receptor antagonists

Article C Peer reviewed Observational

Key takeaways

This review discusses how to combine different drugs for heart and kidney disease. It looks at evidence from large studies to guide treatment order. It is a review of observational and trial data, so it shows links, not proof of cause. It helps doctors plan care for complex patients.

Who did this work

Michal Dubský (Institute of Clinical and Experimental Medicine)

Source

Article · OpenAlex, CKD works · 2026-10-02
https://doi.org/10.36290/vnl.2026.072